# Spironolactone Against Anthracycline-induced Cardiomyopathy

> **NCT02053974** · PHASE4 · COMPLETED · sponsor: **TC Erciyes University** · enrollment: 90 (actual)

## Conditions studied

- Anthracycline Induced Cardiotoxicity

## Interventions

- **DRUG:** Spironolactone
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02053974
- **Lead sponsor:** TC Erciyes University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2014-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02053974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02053974, "Spironolactone Against Anthracycline-induced Cardiomyopathy". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02053974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*